Prostate cancer is a clinically and genetically heterogeneous disease with hereditary factors that are estimated to represent between 40-50% of cases, which include rare to medium high penetrance genetic variants and common low penetrance genetic variants. In particular, it has been demonstrated that HOXB13 and BRCA2 mutations increase the risk of prostate cancer. Mutations in BRCA2 would be responsible for 1-2% of early prostate tumors, conferring a higher risk of suffering prostate cancer at earlier ages (<65 years). Other syndromes associated with a higher risk of prostate cancer exist, among which Lynch syndrome stands out.
Through ClientSite you can filter variants and download your reports